2023 FSHD Society International Research Congress Facioscapulohumeral Muscular Dystrophy (FSHD) Surgeries, Cardiovascular Testing, Mobility Aids and Healthcare Utilization After Diagnosis from a Real-World Data Analysis Phase 1/2 Trial Evaluating AOC 1020 in Adults with FSHD: FORTITUDE Trial Design AOC 1020: An Antibody Oligonucleotide Conjugate (AOC) in Development for the Treatment of FSHD Facioscapulohumeral Muscular Dystrophy (FSHD) Age-related Differences in Symptoms Among Patients Over and Under 40-Years